Skip to main navigation Header - Right - Links Contact Us Social Links Investors & Media About Immatics Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. Stock Quote Immatics N.V. Nov 26, 2021 1:00 PM EST Data Provided by Refinitiv. Minimum 15 minutes delayed. Press & Media Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update read more Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME read more Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer’s 36th Annual Meeting read more FRONT >> News > View All View all IR Toolkit PRINT PAGE EMAIL ALERTS RSS FEEDS CONTACTS Immatics N.V. Immatics Biotechnologies GmbH Paul-Ehrlich-Str. 15 72076 Tuebingen Germany Phone: +49 7071 5397-0 Fax: +49 7071 5397-900 E-Mail: info@immatics.com Immatics US, Inc. 2201 W. Holcombe Blvd., Suite 205 Houston, Texas 77030 Business line: +1 346 204-5400 Fax line: +1 346 204-5391 E-Mail: info@immatics.com Immatics Biotechnologies GmbH Machtlfinger Str. 11 81379 Munich Germany Phone: +49 (89) 540415-0 Fax: +49 (89) 540415-905 E-Mail: info@immatics.com Footer Links Imprint Privacy Policy English Privacy Policy German Privacy Settings Social Links © 2021 Immatics Biotechnologies GmbH By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Accept All Cookies Privacy Settings